E
RXDX

Ergoteles’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Ergoteles’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,791
Closed -$208K – 1709
2021
Q3 		$208K Buy
+8,791
New +$208K 0.01% 972

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Ergoteles's RXDX Position: Q4 2021 in Review

Ergoteles sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q4 2021, closing a stake of 8,791 shares — an estimated $208K sold.

Ergoteles first reported a position in RXDX in Q3 2021 and held it in 1 quarter. The position peaked at $208K in Q3 2021. 74 funds tracked by Wall St. Rank hold RXDX as of Q4 2021.

  • Ergoteles reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Ergoteles sold 8,791 Prometheus Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $208K.
  • Ergoteles first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Ergoteles's Prometheus Biosciences, Inc. Common Stock position peaked at $208K in Q3 2021.
  • 74 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.